CCM
CBAY

Copernicus Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Copernicus Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-278,416
Closed -$2.02M – 20
2020
Q3 		$2.02M Sell
278,416
-8,584
-3% -$45.9K 1.92% 16
2020
Q2 		$1M Buy
+287,000
New +$828K 1.1% 17

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Copernicus Capital Management's CBAY Position: Q4 2020 in Review

Copernicus Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2020, closing a stake of 278,416 shares — an estimated $2.02M sold.

Copernicus Capital Management first reported a position in CBAY in Q2 2020 and held it in 2 quarters. The position peaked at $2.02M in Q3 2020. 145 funds tracked by Wall St. Rank hold CBAY as of Q4 2020.

  • Copernicus Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Copernicus Capital Management sold 278,416 Cymabay Therapeutics shares in Q4 2020, an estimated $2.02M.
  • Copernicus Capital Management first reported a position in Cymabay Therapeutics in Q2 2020 and held it in 2 quarters.
  • Copernicus Capital Management's Cymabay Therapeutics position peaked at $2.02M in Q3 2020.
  • 145 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2020.

Based on Copernicus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.